FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to anti-cancer immunotherapy. Disclosed is the use of a tumor-targeting IL-12 for a combination therapy with IL-7 for inducing and / or stimulating an immune response to cancer in a patient, wherein the cancer is dense tumors or tumors of muscles, bones, nervous system, cartilages, tendons, blood vessels and fat or fibrous tissues, and said induction (stimulation) causes aging of cancer cells or blocking their growth, and / or remission of cancer cells or cancer tissue to cells or tissue of origin, where IL-12 is fused through the N-terminus of its p40 and/or p35 subunits with the C-terminus of the completely human NHS76 antibody or its biologically active fragment, and wherein IL-7 is covalently fused with an immunoglobulin heavy chain or an immunoglobulin heavy chain Fc fragment; use of tumor-targeted IL-12 for combination therapy with IL-2 sarcoma (version); kit for the same purpose comprising (a) a completely human NHS76 antibody directed to a human DNA-histone HI complex presented in tumor necrosis, and fused through the C-terminus to the N-terminus of p40 and/or p35 subunits IL-12, and (b) an immunomodulator and / or an immunocomplementary agent, which is IL-7, covalently fused with a heavy chain of immunoglobulin or an Fc-fragment of the immunoglobulin heavy chain, or representing IL-2 in complex with anti-IL-2 antibody (versions).
EFFECT: stimulated IL-12 patient's immune system not only kills cancer cells, but also uses alternative mechanisms of tumor growth mitigation.
10 cl, 8 dwg, 13 ex
